Nutriband Inc. (NASDAQ: NTRB) announced that Chairman Serguei Melnik will present at Noble Capital Markets' Emerging Growth Virtual Equity Conference on Wednesday, October 8, 2025, at 3 p.m. ET. The presentation will feature a fireside Q&A session with questions from the live virtual audience, and registered investors can schedule one-on-one meetings with Melnik. Interested attendees can register at no cost through the conference's official site.
The company's presentation gains significance due to its focus on developing transdermal pharmaceutical products with abuse-deterrent properties. Nutriband's lead product under development is an abuse-deterrent fentanyl patch incorporating their proprietary AVERSA technology. This technology represents a crucial advancement in addressing the ongoing opioid crisis by preventing abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
A video webcast of the presentation will be available on Channelchek, Noble's investor portal, and archived for 90 days on both Channelchek.com and Nutriband's website at www.nutriband.com. The availability of this archived content ensures broader access for investors who cannot attend the live event.
The importance of Nutriband's technology extends beyond investor interest to significant public health implications. The AVERSA technology platform can be incorporated into any transdermal patch containing drugs with abuse potential, offering a versatile solution to a widespread problem. This development comes at a critical time when opioid abuse continues to pose serious health risks globally, making abuse-deterrent formulations an essential component of comprehensive addiction prevention strategies.
For investors and stakeholders seeking additional information, the latest news and updates relating to NTRB are available in the company's newsroom at https://ibn.fm/NTRB. The virtual conference format allows for broader participation while maintaining the interactive elements traditionally available at in-person investor events.
Nutriband's participation in this emerging growth conference highlights the company's position in the pharmaceutical development sector, particularly in the specialized area of abuse-deterrent transdermal delivery systems. The timing of this presentation provides investors with current insights into the company's progress and future direction amid growing regulatory and public focus on opioid safety measures.
